Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 4, 2020 - Issue 2
Journal homepage
108
Views
2
CrossRef citations to date
0
Altmetric
Case Reports

Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile

Kojiro SatoDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, JapanCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-4105-3726
ORCID Icon,
Yoshimi AizakiDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
,
Yoshihiro YoshidaDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
&
Toshihide MimuraDepartment of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Pages 181-185 | Received 27 Sep 2019, Accepted 25 Dec 2019, Published online: 03 Feb 2020

References

  • Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–994.
  • Furue K, Ito T, Furue M. Differential efficacy of biologic treatments targeting the TNF-alpha/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. Cytokine. 2018;111:182–188.
  • Koizumi H, Tokuriki A, Oyama N, et al. Certolizumab pegol, a pegylated anti-TNF-alpha antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis. J Dermatol. 2017;44(6):723–724.
  • Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebaranz JL, et al. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. Br J Dermatol. 2017;176(3):797–799.
  • van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018;392(10155):1330–1339.
  • Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127(3):385–393.
  • Chen XQ, Yu YC, Deng HH, et al. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol. 2010;30(2):221–225.
  • Dedong H, Feiyan Z, Jie S, et al. Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients. Immunol Lett. 2019;210:33–39.
  • Wang Y, Ito S, Chino Y, et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol. 2010;159(1):1–10.
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725–1725.
  • De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545–R551.
  • Martin JC, Baeten DL, Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin Immunol. 2014;154(1):1–12.
  • Koga T, Ichinose K, Tsokos GC. T cells and IL-17 in lupus nephritis. Clin Immunol. 2017;185:95–99.
  • Satoh Y, Nakano K, Yoshinari H, et al. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus. 2018;27(7):1202–1206.
  • Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700.
  • Ota M, Yanagisawa M, Tachibana H, et al. A significant induction of neutrophilic chemoattractants but not RANKL in synoviocytes stimulated with interleukin 17. J Bone Miner Metab. 2015;33(1):40–47.
  • Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–238.
  • Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967–974.
  • Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity. 2008;29(4):628–636.
  • Madureira P, Pimenta SS, Bernardo A, et al. Off-label use of tocilizumab in psoriatic arthritis: case series and review of the literature. Acta Reumatol Port. 2016;41(3):251–255.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.